Statin‐Associated Muscle‐Related Adverse Effects: A Case Series of 354 Patients
- 1 June 2010
- journal article
- research article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 30 (6) , 541-553
Abstract
Study Objective. To characterize the properties and natural history of 3–hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor (statin)‐associated muscle‐related adverse effects (MAEs).Design. Patient‐targeted postmarketing adverse‐effect surveillance approach coupling survey design with an open‐ended narrative.Setting. University‐affiliated health care system.Subjects. Three hundred fifty‐four patients (age range 34–86 yrs) who self‐reported muscle‐related problems associated with statin therapy.Measurements and Main Results. Patients with perceived statin‐associated MAEs completed a survey assessing statin drugs and dosages; characteristics of the MAEs; time course of onset, resolution, or recurrence; and impact on quality of life (QOL). Cases were assessed for putative drug adverse‐effect causality by using the Naranjo adverse drug reaction probability scale criteria and were evaluated for inclusion in groups for which mortality benefit with statins has been shown. Patients reported muscle pain (93%), fatigue (88%), and weakness (85%). Three hundred patients (85%) met literature criteria for probable or definite drug adverse‐effect causality. Ninety‐four percent of atorvastatin usages (240/255) generated MAEs versus 61% of lovastatin usages (38/62, pConclusion. This study complements available information on the properties and natural history of statin‐associated MAEs, affirming dose dependence and strong QOL impact. The data indicating a dose‐dependent relationship between MAE risk and recurrence suggest lower potency statins or discontinuation may bear consideration for ameliorating symptoms.Keywords
This publication has 66 references indexed in Scilit:
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapyClinical Therapeutics, 2007
- Statin Safety: An Assessment Using an Administrative Claims DatabaseThe American Journal of Cardiology, 2006
- Underappreciated Statin-Induced Myopathic Weakness Causes DisabilityNeurorehabilitation and Neural Repair, 2005
- Drug-Eluting Stent Restenosis Rates?Circulation, 2004
- Oxidation Injury in Patients Receiving HMG-CoA Reductase InhibitorsDrug Safety, 2002
- Efficacy and Safety of Cerivastatin, 0.2 mg and 0.4 mg, in Patients with Primary Hypercholesterolemia: a Multinational, Randomised, Double-blind StudyCurrent Medical Research and Opinion, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Exercise for Female OsteoporosisSports Medicine, 1998
- Mitochondrial Defects of Brain and MuscleNeonatology, 1990